200,000+ products from a single source!
sales@angenechem.com
123018-47-3 | 2-Azaspiro[4.5]decane-2-propanamine, N,N-diethyl-8,8-dipropyl-
CAS No: 123018-47-3 Catalog No: AG000JZ9 MDL No:
Product Description
Catalog Number:
AG000JZ9
Chemical Name:
2-Azaspiro[4.5]decane-2-propanamine, N,N-diethyl-8,8-dipropyl-
CAS Number:
123018-47-3
Molecular Formula:
C22H44N2
Molecular Weight:
336.5982
IUPAC Name:
3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-N,N-diethylpropan-1-amine
InChI:
InChI=1S/C22H44N2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20H2,1-4H3
InChI Key:
SERHTTSLBVGRBY-UHFFFAOYSA-N
SMILES:
CCCC1(CCC)CCC2(CC1)CCN(C2)CCCN(CC)CC
UNII:
MG7D3QD743
Properties
Complexity:
332
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
336.35g/mol
Formal Charge:
0
Heavy Atom Count:
24
Hydrogen Bond Acceptor Count:
2
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
336.608g/mol
Monoisotopic Mass:
336.35g/mol
Rotatable Bond Count:
10
Topological Polar Surface Area:
6.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
6.6
Literature
| Title | Journal |
|---|---|
| Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. | The Journal of biological chemistry 20141205 |
| Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. | Leukemia research 20120301 |
| Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. | Investigational new drugs 20111001 |
| Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. | Cancer research 20110601 |
| Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. | Clinical and experimental gastroenterology 20100101 |
| New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008. | Journal of hematopathology 20080901 |
| A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080401 |
| Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. | Leukemia 20071201 |
| Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. | Blood 20070615 |
| Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. | Leukemia research 20070101 |
| Atiprimod: a multi-functional drug candidate for myeloid and other malignancies. | Leukemia research 20070101 |
| Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. | Molecular cancer therapeutics 20070101 |
| Lipophilicity characterization of new N-phenylamino-azaspiranes as potential anticonvulsant agents. | Biomedical chromatography : BMC 20061101 |
| Efficient approach to the Azaspirane core of FR 901483. | Organic letters 20061012 |
| A clinically relevant SCID-hu in vivo model of human multiple myeloma. | Blood 20050715 |
| Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. | British journal of cancer 20050711 |
| Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. | Blood 20050601 |
| Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis. | Journal of experimental therapeutics & oncology 20041201 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.